Form 4: Celldex Therapeutics Director Granted Stock Options

Celldex Therapeutics reports the grant of stock options to Director Cheryl Cohen under the company's 2021 Omnibus Equity Incentive Plan.

Summary

• Director Cheryl Cohen was granted 26,000 non-qualified stock options on June 25, 2026.
• These options have an exercise price of $34.09 and are exercisable starting June 25, 2027, with an expiration date of June 25, 2036.
• The options were granted under Celldex Therapeutics' 2021 Omnibus Equity Incentive Plan.
• Cheryl Cohen is listed as a Director and 10% owner of Celldex Therapeutics, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation practice (stock option grant) rather than a significant financial event or strategic shift.

Positives

• Grant of stock options to a director can align management's interests with shareholders, potentially driving long-term value.
• The long expiration date of the options (2036) suggests a long-term commitment and incentive structure.

Negatives

• The exercise price of $34.09 is a benchmark that the stock price must exceed for the options to be profitable.
• The filing does not provide details on the performance conditions, if any, associated with the option grant.

Risks

• The value of the stock options is directly tied to the future performance of Celldex Therapeutics' stock price, which is subject to market volatility and company-specific risks.
• If the company's stock price does not appreciate significantly above the exercise price, the options may expire worthless.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance exceeding the exercise price of $34.09 by June 25, 2036.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to incentivize leadership and align their interests with long-term shareholder value creation, especially in companies focused on drug development where significant time horizons are involved.

Stakeholder Impact

• Shareholders: The grant of options could dilute existing share value if exercised, but also aligns director incentives with stock appreciation.
• Employees: May be indirectly impacted by the company's performance, which the director's incentives are tied to.
• Management: The director receives potential future financial benefit tied to company performance.

Next Steps

• Cheryl Cohen may exercise her stock options if the stock price exceeds $34.09.
• The company will continue to operate under its 2021 Omnibus Equity Incentive Plan.

Key Dates

Keywords

stock options, Celldex Therapeutics, CLDX, insider trading, equity incentive plan, director compensation, SEC Form 4